Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2007 May;78(5):470-5.
doi: 10.1136/jnnp.2006.100016. Epub 2006 Nov 10.

Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease

D Devos  1 , P Krystkowiak, F Clement, K Dujardin, O Cottencin, N Waucquier, K Ajebbar, B Thielemans, M Kroumova, A Duhamel, A Destée, R Bordet, L Defebvre
Affiliations
Clinical Trial

Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease

D Devos et al. J Neurol Neurosurg Psychiatry. 2007 May.

Abstract

Background: Therapeutic management of gait disorders in patients with advanced Parkinson's disease (PD) can sometimes be disappointing, since dopaminergic drug treatments and subthalamic nucleus (STN) stimulation are more effective for limb-related parkinsonian signs than for gait disorders. Gait disorders could also be partly related to norepinephrine system impairment, and the pharmacological modulation of both dopamine and norepinephrine pathways could potentially improve the symptomatology.

Aim: To assess the clinical value of chronic, high doses of methylphenidate (MPD) in patients with PD having gait disorders, despite their use of optimal dopaminergic doses and STN stimulation parameters.

Methods: Efficacy was blindly assessed on video for 17 patients in the absence of L-dopa and again after acute administration of the drug, both before and after a 3-month course of MPD, using a Stand-Walk-Sit (SWS) Test, the Tinetti Scale, the Unified Parkinson's Disease Rating Scale (UPDRS) part III score and the Dyskinesia Rating Scale.

Results: An improvement was observed in the number of steps and time in the SWS Test, the number of freezing episodes, the Tinetti Scale score and the UPDRS part III score in the absence of L-dopa after 3 months of taking MPD. The L-dopa-induced improvement in these various scores was also stronger after the 3-month course of MPD than before. The Epworth Sleepiness Scale score fell dramatically in all patients. No significant induction of adverse effects was found.

Interpretation: Chronic, high doses of MPD improved gait and motor symptoms in the absence of L-dopa and increased the intensity of response of these symptoms to L-dopa in a population with advanced PD.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Nutt J G. Long‐term L‐DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease. Exp Neurol 20031849–13. - PubMed
    1. Krack P, Batir A, Van Blercom N.et al Five‐year follow‐up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 20033491925–1934. - PubMed
    1. Krystkowiak P, Blatt J L, Bourriez J L.et al Effects of subthalamic nucleus stimulation and levodopa treatment on gait abnormalities in Parkinson disease. Arch Neurol 20036080–84. - PubMed
    1. Maertens de Noordhout A, Pepin J L, Delwaide P J. Open study of tinazidine in the treatment of freezing gait. 11th International Symposium on Parkinson's disease 26–30 March 1994, Rome
    1. Mizuno Y, Kondo T, Mori H. Various aspects of motor fluctuations and their management in Parkinson's disease. Neurology 199444S29–S34. - PubMed

Publication types

Substances